Biotechnology: a special case for health technology assessment?

This publication has 25 references indexed in Scilit:

• Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis
  New England Journal of Medicine, 1994
• Reflections on the Cost Consequences of the New Gene Technology for Health Policy
  International Journal of Technology Assessment in Health Care, 1994
• Genetic Technology in Health Care: A Global View
  International Journal of Technology Assessment in Health Care, 1994
• Health Care Innovation: Progress Report And Focus On Biotechnology
  Health Affairs, 1994
• Centocor staggered by poor clinical results
  Nature, 1993
• A Comparison of the Costs and Benefits of Recombinant Human Erythropoietin (Epoetin) in the Treatment of Chronic Renal Failure in 5 European Countries
  PharmacoEconomics, 1992
• Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.
  BMJ, 1992
• Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues
  International Journal of Technology Assessment in Health Care, 1991
• Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
  New England Journal of Medicine, 1987
• EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS
  The Lancet, 1986